Live
- Online Dating and AI: It's a New Age Love Story, says GenZ Daters
- Trees take on myriad unique forms in Ompal Sansanwal's solo exhibition
- Party gives everyone opportunities: Punjab Congress chief at Faridkot campaign
- Nikhil, Dhruva & Nikeetaa secure titles in INAC 2024
- Swati Sharma completed 60 parikramas around Shivling to get scene right
- 189 plaints of MCC violations, 23 cases against hate speeches lodged in Karnataka
- Afridi, Chapman rise; Suryakumar remains No.1 T20 batter in latest ICC T20I rankings
- RBI issues red alert on illegal entities in forex market
- Defence Minister Rajnath Singh slams Congress over 'appeasement' politics
- WB moves SC against Calcutta HC order axing 25,753 school jobs
CSIR-CCMB, IPC sign MoU to facilitate regulatory process for biosimilars
Council of Scientific and Industrial Research's constituent laboratory, the Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad
Hyderabad: Council of Scientific and Industrial Research's constituent laboratory, the Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad, and the Indian Pharmacopeia Commission (IPC), Ghaziabad, have joined hands to facilitate the regulatory process for biosimilars and herbal drugs, as per a statement here on Sunday.
The scope of the memorandum of understanding (MoU) signed between CSIR-CCMB and the IPC is the development of biopharmaceutical reference standards and impurities therein, development of monographs for important Monoclonal Antibodies and identification of herbal drugs based on DNA Barcode analysis, a CCMB statement said.
Use of biologics - biological products that function as drugs against diseases - also known as biosimilars, are expanding their presence rapidly in the healthcare sector, including in India.
A 2017 report by the Confederation of Indian Industry (CII) predicts that the biosimilars market in India, that is currently worth about Rs 15,000 crore, is expected to cross the staggering Rs 2,50,000 crore-mark by 2030.
Emergence of biopharmaceutical drugs as a preferred choice for therapy over conventional pharma drugs, requires concerted efforts by various sectors within the country towards production, characterisation and validation of indigenously developed products, the CCMB said.
The agreement was signed by CSIR-CCMB director Rakesh Mishra and IPC's secretary-cum-scientific director G N Singh.
This collaboration, which has come into force with immediate effect, is very important in the current scenario owing to the increase in use of therapeutic proteins and herbal drugs for various diseases, the statement said.
Documentation and characterisation of Indian herbal drugs and phytopharmaceuticals will lead to a significant usage and their export.
This collaborative project will be executed at par with pharmacopeia standards of other countries, it said.
Scientific validation and characterization of herbal drugs will not only help authentication of such drugs but also will bring credibility for this industry, the CCMB added.
